Edition:
United States

Ironwood Pharmaceuticals Inc (IRWD.O)

IRWD.O on Nasdaq

11.50USD
18 Jun 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$11.50
Open
$10.64
Day's High
$11.52
Day's Low
$10.64
Volume
913,850
Avg. Vol
1,454,643
52-wk High
$21.20
52-wk Low
$9.07

Latest Key Developments (Source: Significant Developments)

Sarissa Capital Management Reports 6.1% Stake In Ironwood Pharmaceuticals As Of May 6 - SEC Filing
Thursday, 16 May 2019 05:00pm EDT 

May 16 (Reuters) - Ironwood Pharmaceuticals Inc ::SARISSA CAPITAL MANAGEMENT LP REPORTS A 6.1 PERCENT STAKE IN IRONWOOD PHARMACEUTICALS INC AS OF MAY 6 - SEC FILING.SARISSA CAPITAL MANAGEMENT SAYS PURCHASED IRONWOOD PHARMACEUTICALS' SHARES AS IT BELIEVES SHARES ARE UNDERVALUED.SARISSA CAPITAL MANAGEMENT SAYS VIEW SPINOFF OF IRONWOOD’S RESEARCH AND DEVELOPMENT BUSINESS "AS A GOOD FIRST STEP TOWARDS CREATING SHAREHOLDER VALUE".SARISSA CAPITAL MANAGEMENT SAYS CONTINUE TO BELIEVE THAT IRONWOOD’S EFFORTS TO COMMERCIALIZE IN PRIMARY CARE ARE "SIGNIFICANTLY SUBSCALE".SARISSA CAPITAL MANAGEMENT, ON IRONWOOD’, SAYS EXCITED ABOUT POTENTIAL OF LINZESS.SARISSA CAPITAL MANAGEMENT SAYS BELIEVES IRONWOOD SHOULD SHIFT EFFORTS TO COMMERCIALIZE IN PRIMARY CARE TO A COMPANY ALREADY AT SCALE IN PRIMARY CARE.  Full Article

Ironwood Pharmaceuticals Provides Fourth Quarter And Full Year 2018 Investor Update
Wednesday, 13 Feb 2019 07:00am EST 

Feb 13 (Reuters) - Ironwood Pharmaceuticals Inc ::IRONWOOD PHARMACEUTICALS PROVIDES FOURTH QUARTER AND FULL YEAR 2018 INVESTOR UPDATE.IRONWOOD PHARMACEUTICALS INC - COMMENCED A REDUCTION IN WORKFORCE BY 35 EMPLOYEES, PRIMARILY BASED IN HOME OFFICE.IRONWOOD PHARMACEUTICALS INC - IRONWOOD'S FIELD-BASED SALES FORCE AND EMPLOYEES EXPECTED TO GO TO CYCLERION ARE EXCLUDED FROM WORKFORCE REDUCTION.IRONWOOD PHARMACEUTICALS INC - WILL INCUR AGGREGATE CHARGES IN Q1 OF 2019 OF ABOUT $3 MILLION TO $4 MILLION RELATED TO REDUCTION IN ITS WORKFORCE.IRONWOOD PHARMACEUTICALS INC - QTRLY LOSS PER SHARE $0.10.IRONWOOD PHARMACEUTICALS INC - QTRLY TOTAL REVENUE $130.7 MILLION VERSUS $94.2 MILLION.IRONWOOD PHARMACEUTICALS INC - SEES 2019 TOTAL REVENUE TO BE IN RANGE OF $370 MILLION TO $390 MILLION.IRONWOOD PHARMACEUTICALS INC - SEES 2019 SEPARATION EXPENSES, INCLUDED WITHIN SG&A EXPENSES, TO BE IN RANGE OF $30 TO $40 MILLION.IRONWOOD PHARMACEUTICALS - PROGRESSED SEPARATION OF IRONWOOD & CYCLERION INTO TWO PUBLICLY-TRADED COMPANIES WITH COMPLETION EXPECTED FIRST HALF 2019.IRONWOOD PHARMACEUTICALS- U.S. LINZESS. U.S. NET SALES, AS REPORTED BY CO'S U.S. COLLABORATION PARTNER ALLERGAN PLC, WERE $205.2 MILLION IN Q418, UP 5%.IRONWOOD PHARMACEUTICALS INC - EXPECTS TO PROVIDE GUIDANCE ON 2019 NON-GAAP PROFITABILITY FROM CONTINUING OPERATIONS FOLLOWING COMPLETION OF SEPARATION.IRONWOOD PHARMACEUTICALS INC - DOES NOT INTEND TO GUIDE TO PROFITABILITY FROM CONTINUING OPERATIONS ON A GAAP BASIS IN 2019.  Full Article

Approval Of Linzess Tablets 0.25 Mg In Japan For Additional Indication Of Chronic Constipation
Tuesday, 21 Aug 2018 08:00am EDT 

Aug 21 (Reuters) - Ironwood Pharmaceuticals Inc ::APPROVAL OF LINZESS TABLETS 0.25 MG IN JAPAN FOR ADDITIONAL INDICATION OF CHRONIC CONSTIPATION.IRONWOOD PHARMA - IMPACT OF APPROVAL OF ADDITIONAL CHRONIC CONSTIPATION INDICATION FACTORED INTO FINANCIAL FORECAST FOR FY ENDING MARCH 2019.  Full Article

Ironwood Pharmaceuticals Reports Qtrly Adjusted Loss Per Share $0.28
Monday, 6 Aug 2018 08:00am EDT 

Aug 6 (Reuters) - Ironwood Pharmaceuticals Inc ::IRONWOOD PHARMACEUTICALS PROVIDES SECOND QUARTER 2018 INVESTOR UPDATE.Q2 REVENUE $81 MILLION VERSUS I/B/E/S VIEW $82.6 MILLION.QTRLY LOSS PER SHARE $0.32.QTRLY ADJUSTED LOSS PER SHARE $0.28.TERMINATING LICENSING AGREEMENT WITH ASTRAZENECA FOR U.S. LESINURAD FRANCHISE.IRONWOOD - ON TRACK TO COMPLETE SEPARATION OF IRONWOOD INTO TWO PUBLICLY TRADED COS IN H1 2019.ON TRACK TO COMPLETE SEPARATION OF CO INTO TWO INDEPENDENT, PUBLICLY TRADED COMPANIES IN H1 2019.PLANS TO REDUCE ITS WORKFORCE BY ABOUT 125 EMPLOYEES.IRONWOOD PHARMACEUTICALS - ESTIMATES WILL INCUR AGGREGATE CHARGES IN CONNECTION WITH REDUCTION IN WORKFORCE OF ABOUT $10 MILLION TO $13 MILLION IN 2018.NO LONGER EXPECTS TO BE CASH FLOW POSITIVE IN Q4 OF 2018 DUE TO RESTRUCTURING COSTS.NOW EXPECTS IN 2018 RESTRUCTURING COSTS OF $18 MILLION TO $21 MILLION.IRONWOOD - EXPECTS TO SAVE ABOUT $75 MILLION TO $100 MILLION IN 2019 OPERATING. EXPENSES, PRIMARILY WITHIN SG&A.  Full Article

Ironwood Pharmaceuticals Determined Initial Organizational Designs Of Two New Businesses
Wednesday, 27 Jun 2018 09:25am EDT 

June 27 (Reuters) - Ironwood Pharmaceuticals Inc ::IRONWOOD PHARMACEUTICALS INC - DETERMINED INITIAL ORGANIZATIONAL DESIGNS OF TWO NEW BUSINESSES, INCLUDING EMPLOYEES' ROLES AND RESPONSIBILITIES.IRONWOOD PHARMACEUTICALS- AS PART OF INITIAL ORGANIZATIONAL DESIGNS PROCESS, CO COMMENCED IMPLEMENTATION OF REDUCTION IN WORKFORCE BY ABOUT 40 EMPLOYEES.IRONWOOD PHARMA - INITIAL ORGANIZATIONAL DESIGNS RELATED TO INTENT TO SEPARATE SOLUBLE GUANYLATE CYCLASE BUSINESS FROM COMMERCIAL AND GASTROINTESTINAL BUSINESS.IRONWOOD PHARMACEUTICALS-ESTIMATES THAT IN CONNECTION WITH REDUCTION IN WORKFORCE TO INCUR CHARGES OF ABOUT $5.0 MILLION TO $5.5 MILLION.IRONWOOD PHARMACEUTICALS - EXPECTS TO SUBSTANTIALLY COMPLETE REDUCTION IN ITS WORKFORCE DURING YEAR ENDING DECEMBER 31, 2018.  Full Article

Sun Pharmaceutical Industries Announces Settlement Of Patent Litigation For Generic Linzess In U.S.
Tuesday, 16 Jan 2018 08:38am EST 

Jan 16 (Reuters) - Sun Pharmaceutical Industries Ltd ::SAYS CO'S UNITS HAVE REACHED AN AGREEMENT WITH IRONWOOD PHARMACEUTICALS, INC. AND ALLERGAN PLC.ANNOUNCES SETTLEMENT OF PATENT LITIGATION FOR GENERIC LINZES IN US.COMPANIES TO GRANT CO'S UNITS LICENSE TO MARKET GENERIC VERSION OF LINZESS IN U.S FROM FEB 1, 2031 OR EARLIER UNDER CIRCUMSTANCES.ADDITIONAL DETAILS REGARDING THE SETTLEMENT WERE NOT DISCLOSED..  Full Article

Allergan, Ironwood Announce Settlement With Sun Pharma
Tuesday, 16 Jan 2018 08:30am EST 

Jan 16 (Reuters) - Allergan Plc ::IRONWOOD AND ALLERGAN ANNOUNCE SETTLEMENT WITH SUN PHARMA RESOLVING LINZESS® (LINACLOTIDE) PATENT LITIGATION.SAYS PER SETTLEMENT TERMS, IRONWOOD, CO TO GRANT UNITS OF SUN PHARMA LICENSE TO MARKET GENERIC VERSION OF LINZESS IN U.S. BEGINNING FEB 1, 2031​.SAYS ‍ADDITIONAL DETAILS REGARDING SETTLEMENT WERE NOT DISCLOSED​.SAYS IRONWOOD PHARMACEUTICALS, CO ANNOUNCED COMPANIES REACHED AN AGREEMENT WITH WHOLLY-OWNED UNITS OF SUN PHARMACEUTICAL INDUSTRIES.SAYS ‍AS A RESULT OF SETTLEMENT, ALL HATCH-WAXMAN LITIGATION BETWEEN COMPANIES AND SUN PHARMA REGARDING LINZESS PATENTS TO BE DISMISSED​.  Full Article

Ironwood Pharmaceuticals Sees U.S. Net Sales Of Linzess Of About $700 Million‍​ For FY Ended Dec 31, 2017
Monday, 8 Jan 2018 11:51am EST 

Jan 8 (Reuters) - Ironwood Pharmaceuticals Inc ::IRONWOOD PHARMACEUTICALS INC - EXPECTED U.S. NET SALES OF LINZESS (LINACLOTIDE) OF ABOUT $700 MILLION‍​ FOR FY ENDED DEC 31, 2017.IRONWOOD PHARMACEUTICALS - ‍EXPECTED IRONWOOD REVENUE FROM LINACLOTIDE API SALES TO ASTELLAS OF MORE THAN $100 MILLION FROM JAN 1, 2017 TO DEC 31, 2019​.IRONWOOD PHARMACEUTICALS- EXPECTED REVENUE CAGR FROM THE LINZESS U.S. COLLABORATION WITH ALLERGAN OF ABOUT 75% FOR YEAR ENDED DEC 31, 2014 TO 2017.IRONWOOD PHARMACEUTICALS- EXPECTED LINZESS U.S. NET SALES CAGR OF GREATER THAN 30% FOR YEAR ENDED DEC 31, 2014 TO YEAR ENDED DECEMBER 31, 2017.  Full Article

Ironwood Pharmaceuticals Strengthens Executive Leadership Team
Tuesday, 28 Nov 2017 08:00am EST 

Nov 28 (Reuters) - Ironwood Pharmaceuticals Inc ::IRONWOOD PHARMACEUTICALS STRENGTHENS EXECUTIVE LEADERSHIP TEAM.IRONWOOD PHARMACEUTICALS INC - PROMOTED ‍ GINA CONSYLMAN TO SENIOR VICE PRESIDENT AND CHIEF FINANCIAL OFFICER​.  Full Article

Ironwood Pharma files for potential mixed shelf offering
Thursday, 2 Nov 2017 05:36pm EDT 

Nov 2 (Reuters) - Ironwood Pharmaceuticals Inc :Ironwood Pharmaceuticals Inc files for potential mixed shelf offering; size not disclosed - SEC filing‍​.  Full Article

MOVES-Activist hedge fund Sarissa hires president in push for growth

BOSTON, April 4 Sarissa Capital Management LP, the activist hedge fund run by Alexander Denner that invests in pharmaceutical and healthcare companies, has hired asset management veteran Eric Vincent as president, according to his LinkedIn profile and two people familiar with the matter.